Cancer Research; Molecular Medicine; Oncology; Pharmacology (medical); virology
Disciplines :
Oncology
Author, co-author :
Leparc, Louise ; Université de Liège - ULiège > GIGA > GIGA Neurosciences - Nervous system disorders and therapy ; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Wakimoto, Hiroaki ; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Language :
English
Title :
Engineered retargeting to overcome systemic delivery challenges in oncolytic adenoviral therapy.
Alternative titles :
[fr] Reprogrammation ciblée pour surmonter les défis de la délivrance systémique dans la thérapie oncolytique par adénovirus.
Sato-Dahlman, M., Miura, Y., Hajeri, P., Roach, B., Jacobsen, K., Yamamoto, M., Systemic therapy with the infectivity-selective oncolytic adenovirus by targeting mesothelin. Mol. Ther. Oncol., 33, 2025, 200967.
Miura, Y., Yamasaki, S., Davydova, J., Brown, E., Aoki, K., Vickers, S., Yamamoto, M., Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol. Ther. 21 (2013), 139–148.
Sato-Dahlman, M., Miura, Y., Huang, J.L., Hajeri, P., Jacobsen, K., Davydova, J., Yamamoto, M., CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer. Oncotarget 8 (2017), 76044–76056.
Miller, C.L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D.K., Artandi, S.E., Bertozzi, C.R., Levy, R., Cochran, J.R., Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chem. Biol. 29 (2022), 451–462.e8.
Rojas, L.A., Condezo, G.N., Moreno, R., Fajardo, C.A., Arias-Badia, M., San Martín, C., Alemany, R., Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery. J. Control. Release 237 (2016), 78–88.
Santos, J., Heiniö, C., Quixabeira, D., Zafar, S., Clubb, J., Pakola, S., Cervera-Carrascon, V., Havunen, R., Kanerva, A., Hemminki, A., Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. Cells, 10, 2021, 978.
Dembinski, J.L., Spaeth, E.L., Fueyo, J., Gomez-Manzano, C., Studeny, M., Andreeff, M., Marini, F.C., Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 17 (2010), 289–297.
Faust, J.R., Hamill, D., Kolb, E.A., Gopalakrishnapillai, A., Barwe, S.P., An Immunotherapeutic Target beyond Solid Tumors. Cancers (Basel), 14, 2022, 1550.
Liu, Y., Li, G., Yang, R., Huang, Y., Luo, S., Dang, Q., Li, Q., Huang, D., Huang, Y., Tang, D., et al. The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study. J. Clin. Oncol., 2024 https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5551.
Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., Keith, B., Young, R.M., Engels, B., Sorsa, S., et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight, 3, 2018, e99573.
Ban, W., Guan, J., Huang, H., He, Z., Sun, M., Liu, F., Sun, J., Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy. Nano Res. 15 (2022), 4137–4153.
Garcia-Carbonero, R., Gil Martín, M., Alvarez Gallego, R., Macarulla Mercade, T., Riesco Martinez, M., Guillen-Ponce, C., Vidal, N., Real, F., Moreno, R., Maliandi, V., et al. Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial. Ann. Oncol. 30 (2019), v271–v272.
